A study evaluating differences in characteristics of patients receiving PCSK9 inhibitors versus those who did not.
Latest Information Update: 21 Dec 2016
At a glance
- Drugs Alirocumab (Primary) ; Evolocumab (Primary)
- Indications Atherosclerosis; Hypercholesterolaemia
- Focus Therapeutic Use
- 21 Dec 2016 New trial record
- 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association